This translated into the strong recommendation of the European Society of Cardiology on the use of GLP-1 RAs in patients with T2DM and atherosclerotic cardiovascular disease (ASCVD) in 2019 [73]. This evidence concerns the gene GLP1R and atherosclerosis.